CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

HDL cholesterol

Lipids & LipoproteinsLab test / biomarkerprotectivemodifiablegenetic-causal
89
evidence score

Also known as: HDL cholesterol (low), HDL cholesterol concentration, HDL-cholesterol, hdl-c, high density lipoprotein, high-density lipoprotein (HDL) cholesterol, high-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), high-density lipoprotein cholesterol, 54.3 mg/dL, low HDL, low HDL levels

PREVENT status

✓ Used by PREVENT (core input).

Also used by the Pooled Cohort Equations.

Causal support

genetic causal candidate

Score components
lit volume: 24.7meta-analyses: 20trials: 14.6genetic: 20MR bonus:
Associated genes
CETPLIPC

References (295)

23 meta-analyses / systematic reviews

Clinical trials (28)

NCTTitleStatusTypeInterventions
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT05874141Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, EgyptCOMPLETEDINTERVENTIONALHBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio
NCT02185963Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 DiabetesCOMPLETEDINTERVENTIONALRosuvastatin
NCT02862860Influence of Glycaemic Variability on Oxidative Stress and High-density Lipoprotein (HDL) Function in Type-1 DiabetesCOMPLETEDINTERVENTIONALblood sample, urine sample, installation of Holter
NCT01499420A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic DiseaseCOMPLETEDINTERVENTIONALCSL112 (reconstituted high density lipoprotein), Placebo
NCT01308203Lipid Efficacy and Effects on HDL-C Metabolism of the Extended Release Niacin/Laropiprant Combination Added to Usual Therapy in Patients With Cardiovascular Disease and Low HDL-C That Did Not Achieve the Optional Very Low LDL-C GoalTERMINATEDINTERVENTIONALExtended release niacin/laropiprant, placebo
NCT01414166A 16-Week, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Extended Release Niacin/Laropiprant in South and Southeast Asians Not on a Lipid Modulating Agent, With Decreased High-Density Lipoprotein Cholesterol and Low- Density Lipoprotein Cholesterol at or Below NCEP ATP III GoalTERMINATEDINTERVENTIONALERN/LRPT, placebo
NCT01284582Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dlCOMPLETEDINTERVENTIONALATH03
NCT01025492Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C)TERMINATEDINTERVENTIONALTrilipix, placebo
NCT01342666Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical TrialCOMPLETEDINTERVENTIONALTomato consumption, Cucumber consumption
NCT00768274A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)COMPLETEDINTERVENTIONALRVX000222, Placebo
NCT00986986Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol LevelsCOMPLETEDINTERVENTIONALextended release niacin
NCT00461630A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/LaropiprantCOMPLETEDINTERVENTIONALER niacin/laropiprant, simvastatin, ezetimibe/simvastatin
NCT00408148A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk FactorsTERMINATEDINTERVENTIONALPlacebo, Rimonabant
NCT00261352A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a StatinTERMINATEDINTERVENTIONALTesaglitazar, Metformin, Fenofibrate
NCT00688558A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL LevelsCOMPLETEDINTERVENTIONALJTT-705 600 mg and simvastatin 40 mg, Placebo and simvastatin 40 mg
NCT00689442A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL LevelsCOMPLETEDINTERVENTIONALJTT-705 600 mg and atorvastatin 20 mg, Placebo and atorvastatin 20 mg
NCT01921010Benefit of Elevation of HDL-cholesterol/Triglyceride Lowering on Cardiovascular Outcomes in WomenCOMPLETEDINTERVENTIONALNiaspan, Placebo
NCT02585869A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI-1027 in Patients With Low HDL-C and Either Normal or Elevated TriglyceridesCOMPLETEDINTERVENTIONALGemcabene 150 mg, Gemcabene 300 mg, Gemcabene 600 mg
NCT06190834Relationship Between High Density Lipoprotein Subtypes and Prognosis in Coronary Heart Disease Patients.RECRUITINGOBSERVATIONAL
NCT07476248The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes MellitusNOT YET RECRUITINGOBSERVATIONAL
NCT05126043Triglyceride/High Density Lipoprotein-cholesterol Ratio as a Novel Marker of Atherosclerosis in Patients With Acute Coronary SyndromeCOMPLETEDOBSERVATIONALTriglycerides/high density lipoprotein ratio
NCT04835207Metabolic Profile as a Predictor of No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention ( PCI ) .UNKNOWNOBSERVATIONAL1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
NCT04979377Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological MechanismsCOMPLETEDOBSERVATIONALClinical hyperandrogenism assessment, Total testosterone (ng/dL), A1c (%)
NCT03724825Correlation of Serum Adropin to Testosterone and Adiponectin in Obese MenCOMPLETEDOBSERVATIONALlipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)), Total testosterone, Adropin
NCT04390711An Observational Cross-sectional Study to Compare Carbamylated High-density Lipoprotein Levels Among Normal Subjects, Type 2 Diabetes Mellitus Patients With and Without Coronary Heart Disease.COMPLETEDOBSERVATIONALHigh density lipoprotein isolation, detection and in-vitro study.
NCT00912236Evaluation of High-Density Lipoprotein in Obesity StudyTERMINATEDOBSERVATIONAL
NCT01687686Differential Effects of Total Cholesterol, Non-HDL Cholesterol and Triglycerides on Initial Presentation of Specific Cardiovascular Diseases (a CALIBER Study)UNKNOWNOBSERVATIONAL

Genetic associations (201)

showing top 80 by significance
VariantGene(s)TraitpOR/βStudy
CETP, HERPUD11e-5902—GCST90239649
CETP, HERPUD11e-30770.22933 unit increaseGCST90239652
CETP, HERPUD11e-29670.22 mmol/L increaseGCST90501136
CETP, HERPUD11e-29500.21 mmol/L increaseGCST90501141
CETP, HERPUD11e-29290.21 mmol/L increaseGCST90501134
CETP, HERPUD11e-28610.21 mmol/L increaseGCST90501140
CETP, HERPUD11e-27920.21 mmol/L increaseGCST90501142
CETP, HERPUD11e-27410.21 mmol/L increaseGCST90501113
CETP, HERPUD11e-27350.21 mmol/L increaseGCST90501112
CETP, HERPUD11e-26960.21 % decreaseGCST90501299
CETP, HERPUD11e-26500.2 mmol/L increaseGCST90501138
CETP, HERPUD11e-25630.2 % increaseGCST90501187
CETP, HERPUD11e-25070.2 nm increaseGCST90501118
CETP, HERPUD11e-24340.2 mmol/L increaseGCST90501114
CETP, HERPUD11e-23930.2327 unit increaseGCST90018956
CETP, HERPUD11e-22670.19 mmol/L increaseGCST90501115
CETP, HERPUD11e-20530.19 mmol/L increaseGCST90501186
CETP, HERPUD11e-20190.18 mmol/L increaseGCST90501296
CETP, HERPUD11e-20030.19 mmol/L increaseGCST90501182
CETP, HERPUD11e-19580.18 mmol/L increaseGCST90501117
CETP, HERPUD11e-19530.19 mmol/L increaseGCST90501184
CETP, HERPUD11e-18610.18 g/l increaseGCST90501098
CETP, HERPUD11e-18330.2 % decreaseGCST90501163
CETP, HERPUD11e-17610.18 % decreaseGCST90501145
CETP, HERPUD11e-17550.17 mmol/L increaseGCST90501301
CETP, HERPUD11e-17350.17 mmol/L increaseGCST90501294
CETP, HERPUD11e-17290.18 mmol/L increaseGCST90501189
CETP, HERPUD11e-17130.18 % increaseGCST90501183
CETP, HERPUD11e-17000.17 mmol/L increaseGCST90501300
CETP, HERPUD11e-16620.18 % decreaseGCST90501191
CETP, HERPUD11e-16420.17 mmol/L increaseGCST90501302
CETP, HERPUD11e-16260.17 % increaseGCST90501135
CETP, HERPUD11e-15680.19 % increaseGCST90501169
CETP, HERPUD11e-15390.17 % increaseGCST90501137
CETP, HERPUD11e-15080.17 % decreaseGCST90501167
CETP, HERPUD11e-14950.16 mmol/L increaseGCST90501188
CETP, HERPUD11e-14750.17 % decreaseGCST90501193
CETP1e-14660.2474 unit increaseGCST90019510
CETP, HERPUD11e-14540.16 mmol/L increaseGCST90501116
CETP, HERPUD11e-13050.222497 mmol/L increaseGCST90500359
CETP, HERPUD11e-12240.15 mmol/L increaseGCST90501190
CETP, HERPUD11e-12200.215936 mmol/L increaseGCST90500436
CETP1e-12130.230733 % increaseGCST90500380
CETP, HERPUD11e-12110.143745 unit decreaseGCST010242
CETP, HERPUD11e-12100.16 % decreaseGCST90501155
CETP, HERPUD11e-11990.16 % decreaseGCST90501261
CETP, HERPUD11e-11870.21186 mmol/L increaseGCST90500410
CETP, HERPUD11e-11790.211616 mmol/L increaseGCST90500324
CETP, HERPUD11e-11650.209411 mmol/L increaseGCST90500474
CETP, HERPUD11e-11620.15 mmol/L increaseGCST90501280
CETP, HERPUD11e-11600.22094 % decreaseGCST90498185
CETP, HERPUD11e-11300.213053 mmol/L increaseGCST90497437
CETP, HERPUD11e-11050.15 % increaseGCST90501185
CETP, HERPUD11e-10720.208984 % decreaseGCST90498049
CETP, HERPUD11e-10250.208178 % increaseGCST90498267
CETP, HERPUD11e-10200.3049 unit increaseGCST90244005
CETP, HERPUD11e-10110.13 % decreaseGCST90501303
CETP, HERPUD11e-9750.14 % increaseGCST90501239
CETP, HERPUD11e-9500.13 % decreaseGCST90501245
CETP, HERPUD11e-9180.195465 % decreaseGCST90499782
CETP1e-8780.1925 unit increaseGCST90019495
CETP, HERPUD11e-8430.12 mmol/L increaseGCST90501298
CETP, HERPUD11e-8370.13 % decreaseGCST90501159
CETP, HERPUD11e-7690.241 unit increaseGCST002223
CETP, HERPUD11e-7650.171995 % increaseGCST90499425
CETP, HERPUD11e-7480.13 % decreaseGCST90501315
CETP, HERPUD11e-7330.188806 mmol/L increaseGCST90497430
CETP, HERPUD11e-7270.11 % increaseGCST90501305
CETP, HERPUD11e-7240.11499 unit decreaseGCST010241
CETP, HERPUD11e-7210.166413 mmol/L increaseGCST90500398
CETP, HERPUD11e-7050.2751 unit increaseGCST011348
CETP, HERPUD11e-6920.180601 mmol/L increaseGCST90500373
CETP1e-6820.191267 % increaseGCST90500383
CETP, HERPUD11e-6450.11 % decreaseGCST90501143
CETP, HERPUD11e-6440.12 ratio decreaseGCST90501100
CETP, HERPUD11e-6330.178405 % decreaseGCST90498181
CETP, HERPUD11e-5980.157786 % decreaseGCST90498119
CETP, HERPUD11e-5880.1 % decreaseGCST90501139
CETP, HERPUD11e-5750.1 mmol/L increaseGCST90501227
CETP, HERPUD11e-5700.1 mmol/L increaseGCST90501244